HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

North American fragrance sales increased 3% in Q4 and 9% in 2004, led by fragrance wins like Armani Mania, Island Michael Kors, Kenneth Cole Reaction and Dior Pure Poison,International Flavors & Fragrances reports during Jan. 26 sales and earnings release. Consolidated net sales grew 1% in Q4 to $468.2 mil., but fell 4% in constant currencies, compared to reported sales a year ago, which included sales of the divested fruit preparations business. Compared to pro forma results, sales fell 3.4%. Net income increased 7.4% to $40.9 mil., including restructuring charges. For the year, sales increased 6.9% to $2.03 bil., or 2% in constant currencies, led by 13% growth in fine fragrances and 7% gains in functional and aroma chemical fragrance sales. Sales increased 8.5% compared to pro forma sales a year ago. Net income for the year was up 13.6% to $196.1 mil., including restructuring charges...

You may also be interested in...

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts